# Annovis Bio (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

* Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023
* The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases
* Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases

 Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is continuing to make significant strides in the field of neurodegenerative diseases with its latest patent filings. The recent announcement is the filing of a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.

 “The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis (https://ibn.fm/5vAuO). “This achievement will allow us not only to continue advancing our…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/annovis-bio-nyse-anvs-files-new-composition-of-matter-patent-for-buntanetap/)
                    

[Newsramp.com TLDR](None) 



[Reddit Post](https://www.reddit.com/r/newsramp/comments/1f2feky/annovis_bio_nyse_anvs_makes_strides_in/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/248/27/pavehQu_.webp)